Introduction: Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases of unclear etiology. There is evidence, that genetic, immunologic, and environmental factors contribute to its pathology. Autoimmune oophoritis has been proposed as one of the possible etiologies of diminished ovarian reserve. Pro-inflammatory cytokine - tumor necrosis factor alpha (TNFα) is implicated in the pathogenesis of oophoritis and psoriasis. Certolizumab is an anti-TNFα monoclonal antibody studied now in the treatment of psoriasis. Here we present a case of a patient diagnosed with psoriasis, PsA and diminished ovarian reserve, in which we observed normalization of ovarian reserve surrogates after treatment with certolizumab. To our knowledge, it is a first such a case report in the literature.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Maturitas
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Published online: August 06, 2019
© 2019 Published by Elsevier Inc.